Orion-yhtyma Oy

Other

Hormos Nutraceutical Oy Ltd.

Orion Corporation

Farmos Group Ltd.

Forendo Pharma Ltd

Hormos Medical Oy Ltd.

Hormos Medical Corporation

Therapeutica Borealis Oy

Nippon Kayaku Kabushiki Kaisha

Farmos-yhtyma Oy

Therapeutica Borealis Oy C/o Avance Attorneys Ltd.

Hormors Medical Oy Ltd.

Lauri V Kangas

Risto A Lammintausta

Arto J Karjalainen

Kauko O Kurkela

Markku Ahotupa

Tetsushi Saino

Hisao Ekimoto

Risto Santti

Michael W DeGregorio

Mikko Unkila

Osamu Miyazaki

Michinori Koyama

Anni Warri

Christer Granberg

Arja Marketta Kalapudas

Kaija Halonen

Guillermo L Blanco

Kalervo Väänänen

Junpei Itoh

Reijo J Toivola

Pasi Koskimies

Leena Hirvelä

Matti Rihko

Pirkko Harkonen

Marja-Liisa Soderwall

Niina Saarinen

Tomi Streng

Maire Eloranta

Kalervo Vaananen

Christer Eckerman

Aire Maria Laine

Antti Talo

Sari M&auml;kel&auml;

Anni W&auml;rri

Hannu K Sundquist

Valerie Wiebe

Harry Gosta Jalonen

Tatu Miettinen

John E Eriksson

Reino O Pelkonen

Marja-Liisa Sodervall

Helena Korte

Patrik Eklund

Marja Södervall

Sari Mäkelä

Pirkko Härkönen

Marja-Liisa S&ouml;dervall

Mervi Hiilovaara-Teijo

Hannu K Sunduiqst

Kalervo Vaan&auml;nen

Anna Lindholm

Rainer Sjohölm

Chester Eckerman

Junpei It&ouml;h

Janne Komi

Eero Mantyla

Merja Perälä

Anni Wärri

Hannu U Jalonen

Terttu M Heikkila

Kalevi Heiskanen, Deceased

Marja-Liisa Södervall

Eva Nagy

Edward Baral

Istvan Berczi

Pirkko H&auml;rk&ouml;nen

Michael W Degregorio

Leena HirvelÄ

The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.

Medicine for Covid-19 and treatment

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.

Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17&#x3b2;-hydroxysteroid dehydrogenase

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

Method for the alleviation of dyspareunia in women

Novel phenolic esters of lignans, and pharmaceutical compositions, dietary supplements, and food products containing these esters.

Lignan derivatives

The invention relates to a method of inhibiting myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan, where said lignan is enterolactone. The invention is further directed to a method inhibiting myeloperoxidase activity or oxidative burst of macrophages in an individual by administering to the individual an effective amount of a lignan where said lignan is enterolactone or hydroxymatairesinol or a mixture. Finally, the invention is directed to a method of inhibiting oxidative burst or myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan which is hydroxymatairesinol.

Method of inhibiting overactivity of phagocytes or lymphocytes in an individual

A food product containing an effective amount of an active agent which is hydroxymatairesinol, a geometric isomer or stereoisomer thereof, or an acceptable salt thereof, or a mixture thereof, where the food product is selected from the group consisting of a nutritional supplement and a nutrient. The food product can increase the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on the administration of hydroxymatairesinol to the person.

Food product comprising hydroxymatairesinol

The invention provides novel selective estrogen receptor modulator compounds of the general formula:wherein R1 and R2, which are the same or different are

Triphenylalkene derivatives and their use as selective estrogen receptor modulators

This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.

Food additive or product or a pharmaceutical preparation, comprising hydroxymatairesinol

Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Remedy for autoimmune diseases

USE OF HYDROXYMATAIRESINOL FOR PREVENTION OF CANCERS, NON-CANCER, HORMONE DEPENDENT DISEASES AND CARDIOVASCULAR DISEASES BY HYDROXYMATAIRESINOL, AND A PHARMACEUTICAL PREPARATION, FOOD ADDITIVE AND FOOD PRODUCT COMPRISING HYDROXYMATAIRESINOL

Growing community of inventors

Turku, Finland

Lauri V Kangas